Clinical Trial Update: Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) [Phase 2]

View source ↗

Summary

Clinical trial update outlining plans to study IDH1 inhibitor olutasidenib in combination with ASTX727 and venetoclax for acute myeloid leukemia, add olutasiden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Olutasidenib (olutasidenib)
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: NOT_YET_RECRUITING